Format

Send to

Choose Destination
Thromb Res. 2019 Sep;181 Suppl 1:S47-S53. doi: 10.1016/S0049-3848(19)30367-6.

Women, thrombosis, and cancer.

Author information

1
Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04) Centre de Référence des Maladies auto-immunes systémiques Rares d'ile-de-France, Filière FAI2R, F-75010 Paris, France; Département de Médecine, Université McGill, Montreal, Québec, Canada. Electronic address: dominique.farge-bancel@aphp.fr.
2
Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Oncologie Médicale, F-75010, Paris, France.
3
Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service d'Hématologie Biologique; Sorbonne Université, INSERM UMRS_1166, Institute of Cardiometabolism And Nutrition, F-75013 Paris, France.

Abstract

Venous thromboembolism (VTE) is a major common complication in cancer patients. Risk-adapted thromboprophylaxis and antithrombotic therapy for patients diagnosed with VTE can reduce the recurrence of VTE events. Thrombotic risk varies according to cancer type, stage, and comorbidities. The current review analyzes most recent data and provides clinical guidance for the management of women with cancer-associated thrombosis.

KEYWORDS:

Anticoagulant; Cancer; Contraception; Hormone therapy; Pregnancy; Venous thromboembolism; Women's health issues

PMID:
31477228
DOI:
10.1016/S0049-3848(19)30367-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center